ADAM19 participated in peritoneal fibrosis by regulating M2 macrophage polarization in peritoneal dialysis patients

Kunyue Xu1, Jin Yu1,2, Minhui He1

  • 1Department of Nephrology, Hangzhou TCM Hospital Affiliated to Zhejiang Chinese Medical University, 453 stadium Road, Hangzhou, 310000, Zhejiang, People's Republic of China.

Scientific Reports
|May 2, 2026
PubMed

Insights

ADAM19 drives peritoneal fibrosis in dialysis patients by promoting M2 macrophage polarization. Higher ADAM19 levels predict reduced dialysis adequacy, suggesting its potential as a biomarker for peritoneal dialysis function.

Area of Science:

  • Nephrology
  • Immunology
  • Biochemistry

Background:

  • Peritoneal fibrosis, linked to M2 macrophage polarization, hinders long-term peritoneal dialysis (PD) efficacy.
  • The role of ADAM19 in PD-associated peritoneal fibrosis is not well understood, despite its known involvement in fibrosis elsewhere.

Purpose of the Study:

  • To investigate the role of ADAM19 in peritoneal fibrosis progression in PD patients.
  • To explore the relationship between ADAM19 expression, macrophage polarization, and PD adequacy.
  • To assess ADAM19's potential as a biomarker for peritoneal dialysis function.

Main Methods:

  • Analysis of peritoneal dialysis effluent from PD patients at varying dialysis durations.
  • Detection of ADAM19, Notch1, fibrosis markers, chemokines, and inflammatory factors using real-time PCR and western-blot.
  • Macrophage identification via flow cytometry and establishment of mouse models for peritoneal fibrosis.

Main Results:

  • Long-term PD patients exhibited elevated fibrotic proteins, inflammatory factors, and increased M2 macrophage polarization compared to short-term patients.
  • ADAM19 expression correlated positively with dialysis duration and Kt/v, showing predictive value for dialysis adequacy (AUROC 0.738).
  • ADAM19/Notch1 signaling pathway was implicated in promoting M2 macrophage polarization, especially with prolonged high-glucose dialysis exposure in mice.

Conclusions:

  • ADAM19 is significantly associated with peritoneal fibrosis progression and M2 macrophage polarization in PD patients.
  • Elevated ADAM19 levels are linked to reduced peritoneal dialysis adequacy.
  • ADAM19 shows promise as a novel biomarker for assessing peritoneal ultrafiltration function in PD patients.